Topics:

CA4P Gets Orphan Drug Status

CA4P Gets Orphan Drug Status

Waltham, Mass—The FDA has granted Oxigene's combretastatin A4P (CA4P) orphan drug status for treatment of ovarian cancer. In a phase Ib trial, advanced ovarian cancer patients who had failed previous therapy showed a 67% response rate to CA4P plus carboplatin and paclitaxel, the company said in a news release. This combination is currently being evaluated in a phase II trial in women with platinum-resistant ovarian cancer.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.